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The objective of the design and manufacture of the 
compressed tablet is to deliver orally the correct amount of 
drug in the proper form, over a period of time and in the 
desired location, and to have its chemical integrity 
protected to that point. The prime objective of any 
pharmaceutical plant is to manufacture products of 
requisite attribute and quality consistently, at the lowest 
possible cost. Numerous features are required to ensure 
product quality, such as chemical and physical stability, 
suitable preservation against microbial contamination if 
appropriate, uniformity of dose of drug, acceptability to 
users including prescriber and patient, as well as suitable 
packing, labeling, and validation1.It is through careful 
design and validation of both the process and process 
controls that a manufacturer can establish a high degree of 
confidence that all manufactured units from successive lots 
will be acceptable. Successful validation of a process may 
reduce the dependence upon intensive in-process and 
finished product testing. In most cases, end-product testing 
plays a major role in assuring that quality assurance goals 
are met; i.e., validation and end-product testing are not 
mutually exclusive2. 
The FDA in „„Guidelines on General Principles of Process 
Validation‟‟ defines process validation as „„establishing 
documented evidence which provides a high degree of 
assurance that a specific process will consistently produce 
a product meeting its predetermined specifications and 
quality characteristics‟‟.According to EMEA, “Process 
validation can be defined as documented evidence that the 
process, operated within established parameters, can 
perform effectively and reproducibly to produce a medical 
product meeting its predetermined specifications and 
quality attributes”3. 
Tablet as a dosage form comprises a mixture of active 
substances and excipients, usually in powder form, pressed 
or compacted into a solid. The excipients can include 
binders, glidants (flow aids) and lubricants to ensure 
efficient tabletting; disintegrants to promote tablet break-
up in the digestive tract; sweeteners or flavors to enhance 
taste; and pigments to make the tablets visually attractive. 
A polymer coating is often applied to make the tablet 
smoother and easier to swallow, to control the release rate 
of the active ingredient, to make it more resistant to the 
environment (extending its shelf life), or to enhance the 
tablet's appearance. The manufacturing of tablets involves 
extensive powder handling. The powder must be blended 
for uniformity and converted into the dosage form either 
through compression. Typical requirements include 
weighing, blending, mixing/granulation areas, 
compression, and coating areas4. 
OBJECTIVES OF PROCESS VALIDATION
 
 In addition to the individual equipment, the 
manufacturing process must be validated. 
 The goal is to create a robust manufacturing process 
that consistently produces a drug product with 
minimal variation that adheres to quality criteria of 
purity, identity, and potency. 
 Engineers should draft and execute a validation plan 
for the manufacturing process in order to satisfy 
guidelines. The validation plan usually involves just a 
PQ section. 
 Just as equipment validation, after the initial 
validation, major changes will result in the need for 
subsequent revalidation. 
 Process validation will ensure a robust product which 
is highly reproducible over time. 
REASON FOR PROCESS VALIDATION 
The possible reason of performing process validation may 
include: 
 New product or existing products as per SUPAC 
changes. 
 Change in site of manufacturing. 
 Change in batch size. 
 Change in equipment. 
 Change in process existing products. 
 Change in composition or components. 
 Change in the critical control parameters. 
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 Change in vendor of API or critical incipient. 
 Change in specification on input material. 
 Abnormal trends in quality parameters of product 
through review during Annual Product Review (APR). 
 Trend of Out of Specification (OOS) or Out of Trend 
(OOT) in consecutive batches5. 
Benefits of Process Validation 
 Consistent through output. 
 Reduction in rejections and reworks. 
 Reduction in utility cost. 
 Avoidance of capital expenditures. 
 Fewer complaints about process related failure. 
 Reduced testing process and finished goods. 
 More rapid and accurate investigations into process 
deviation. 
 More rapid and reliable start-up of new equipment. 
 Easier scale-up from development work. 
 Easier maintenance of equipment. 
 Improve employee awareness of processes. 
 More rapid automation6. 
TYPES OF PROCESS VALIDATION
7,8,9 
The guidelines on general principles of process validation 
mentions four types of validation: 
A) Prospective validation 
B) Concurrent validation 
C) Retrospective validation 
D) Revalidation 
Change Control 
A consistent achievement of product quality is dependent 
on the availability of defined/approved/ validated 
procedures and the application and adherence to these 
procedures by trained personnel. In the event that any 
change is to be introduced into the production operation, it 
is important to evaluate its potential impact and where 
necessary provide appropriate evaluation and/or actions. 
Written procedures should be in place to describe the 
actions to be taken if a change is proposed to a product 
component, process equipment, process environment, 
processing site, method of production or testing or any 
other change that may affect product quality or support 
system operations. Any proposals for changes should be 
drafted, reviewed, and approved by the appropriate 
organizational units, and reviewed and approved by the 
quality control unit7, 10 . 
Major Phases in Validation:
11,12 
Phase 1: Pre-Validation Phase or the Qualification Phase 
Phase 2: Process Validation Phase (Process Qualification 
phase) 
Phase 3: Validation Maintenance Phase 
THE REGULATORY BASIS FOR PROCESS 
VALIDATION 
The concept of process validation from its beginnings in 
the early 1970s through the regulatory aspects associated 
with current good manufacturing practice (cGMP) 
regulations and the application thereof to various 
analytical, quality assurance, pilot plant, production, and 
sterile product and solid dosage forms considerations. 
In the early 1990s, the concept of preapproval inspection 
(PAI) was born and had as one of its basic tenets the 
assurance that approved validation protocols and schedules 
were being generated and that comprehensive 
development, scale-up, and biobatch and commercial batch 
validation data were required in order to achieve a 
successful regulatory PAI audit. There are several 
important reasons for validating a product and/or process. 
First, manufacturers are required by law to conform to 
cGMP regulations. Second, good business dictates that a 
manufacturer avoids the possibility of rejected or recalled 
batches. Third, validation helps to ensure product 
uniformity, reproducibility, and quality. 
Although the original focus of validation was directed 
towards prescription drugs, the FDA Modernization Act of 
1997 expanded the agency‟s authority to inspect 
establishments manufacturing over-the-counter (OTC) 
drugs to ensure compliance with cGMP. 
Once the concept of being able to predict process 
performance to meet user requirements evolved, FDA 
regulatory officials established that there was a legal basis 
for requiring process validation. The ultimate legal 
authority is Section 501(a)(2)(B) of the FD&C Act, which 
states that a drug is deemed to be adulterated if the 
methods used in, or the facilities or controls used for, its 
manufacture, processing, packing, or holding do not 
conform to or were not operated or administrated in 
conformity with cGMP. The cGMP regulations for 
finished pharmaceuticals, 21 CFR 210 and 211, were 
promulgated to enforce the requirements of the act. FDA 
has the authority and responsibility to inspect and evaluate 
process validation performed by manufacturers. The 
cGMP regulations for validating pharmaceutical (drug) 
manufacturing require that drug products be produced with 
a high degree of assurance of meeting all the attributes 
they are intended to possess (21 CFR 211.100(a) and 
211.110(a)).12,13,14,15 
STRATEGY FOR INDUSTRIAL PROCESS 
VALIDATION OF SOLID DOSAGE FORMS 
The strategy selected for process validation should be 
simple and straightforward. The following five points 
gives strategy for process validation: 
 The use of different lots of raw materials should be 
included. i.e., active drug substance and major 
excipients. 
 Batches should be run in succession and on different 
days and shifts (the latter condition, if appropriate). 
 Batches should be manufactured in the equipment and 
facilities designated for eventual commercial 
production. 
 Critical process variables should be set within their 
operating ranges and should not exceed their upper 
and lower control limits during process operation. 
Output responses should be well within finished 
product specifications. 
 Failure to meet the requirements of the Validation 
protocol with respect to process input and output 
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control should be subjected to process requalification 
and subsequent revalidation following a thorough 
analysis of process data and formal discussion by the 
validation team.12,13 
GUIDELINES FOR PROCESS VALIDATION OF 
SOLID DOSAGE FORMS 
Numerous factors should be considered when developing 
and validating solid dosage forms. As a means of 
providing a broad overview of these validation criteria, the 
following checklist/guideline as in Table 1, is provided for 
tablets and dry-filled capsules for inclusion in an in depth 
validation program. Some of these unit operations will not 
be applicable for every solid dosage form (e.g., direct 
compression tablets and uncoated tablets).
 
Table 1: Check list of Validation and Control Documentation 
S.N. Selection of cGMP Validation and Control Documentation 
1. Introduction Establishing of QA & PV functions 
2. Organization and personnel Establishment and facility installation and qualification 
3. Buildings and facilities Plant and facility installation qualification 
Maintenance and sanitation 
Microbial and pest control 
4. Equipment Installation and qualification cleaning methods. 
5. Air and water quality Water treatment and steam systems air, heat, and vacuum handling. 
6. Control of raw material, in-process 
material, product 
Incoming components 
Manufacturing non-sterile products 
7. Production and process controls Process control systems (instruments and computers) 
8. Packing and labeling controls Depyrogenation, sterile packing, filling, and closing. 
9. Holding and distribution Facilities 
10. Laboratory controls Analytical methods 
11. Records and reports Computer systems 
12. Returned and salvage drug products Batch processing 
 
 
PROTOCOL FOR PROCESS VALIDATION: 
The protocol for process validation is given from the tables 2, 3, 4 & 5 as follows: 
Table 2: Protocol for title page in industry 
Name of the company 
Process validation protocol 
Product:  Page No. : 1 of ……. 
Protocol No. :  Version No. : 
Product name :  
Label claim :  
Master Formula Record (MFR) No. :  
Batch Manufacturing Record (BMR) No. :  
Effective Date :  
 
Table 3: Protocol approval 
 Prepared By Checked by Approved by 
Signature      
Date       
Name      
Department Quality Assurance (QA)/Research and 
development (R&D) 
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Table 4: Table of Contents 
S. No. Title Page No. 
1 Protocol Approval Sheet  
2 Table of contents  
3 Objective  
4 Scope  
5 Validation term and responsibility  
6 Steps for validation and acceptance criteria  
7 Process flow chart  
8 Procedure  
9 Form – A : Review of raw material/packing material  
10 Form – B : Evaluation of active raw material  
11 Form – C : Evaluation of inactive raw material  
12 Form – D : Qualification of equipment  
13 Form – E : Test instrument calibration  
14 Form – F : Dry mixing  
15 Sampling point diagram of RMG  
16 Form – G : Wet mixing  
17 Form – H : Drying  
18 Sampling point diagram of FBD  
19 Form – I : Lubrication  
20 Sampling point diagram of RMG  
21 Form – J : Compression  
22 Form – K : Coating  
23 Form – L : Bulk packing  
24 Re validation criteria  
25 Change control  
26 Stability  
27 Deviations  
28 Conclusion  
29 Report and Approval  
 
Table 5: Validation team and Responsibilities 




Executive/Officer To coordinate the entire validation process by scheduling meetings and 
discussions with production, quality control and quality assurance. 
Preparation of preliminary validation protocol, master formula record, 
monitoring the process, compiling and analyzing data and test results and 
preparing the final report. To review the preliminary validation documents. 
Quality assurance Officer To coordinate the entire validation process by scheduling meetings and 
discussions with the team. 
Preparation of validation protocol, monitoring the process, compiling and 
analyzing data and test results and preparing the final report. 
To review of validation documents. 
Production Officer To participate in performing the validation steps during manufacturing 
processes. 
To assist in collection of data. 
Quality control Officer To test and report the test results 
Quality assurance General manager 
 
Quality assurance 
To approve the process validation protocol and report. 
To review of validation documents. 
To approve the process. 
 
STEPS FOR VALIDATION AND ACCEPTANCE CRITERIA 
The following steps (Table 6) are used in industry for validation of tablets in wet granulation process.12, 16 
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Table 6: Steps for validation and acceptance criteria in wet granulation process 
S.N.  Steps Control Variable Critical Parameters 
to be checked 
Acceptance criteria 
1 Dry mixing Time Mixing time  Mixing time:…………min 
Impeller speed Mixing speed Impeller speed: 
...(slow/medium/high)±5RPM. 
Content uniformity : 90%-110% 




Time Mode and time of 
addition 
Depending up on the formulation. 
Temperature, 
solvent used 
3 Drying Inlet/outlet 










Final drying : …….°C±5°C 
Loss on drying : ……….% below 3% 
or depending 
on formulation 
4 Lubrication  Time Mixing time and 
speed 
 
Mixing time: ………min. 
Speed slow: ……..rpm. 
Content uniformity : 
Physical parameters – for information. 
Blender/granulator 
speed 
5. Compression  
 
Pressure and turret 
speed 
 




Average weight:  mg±5%,7.5%,10%. 
Uniformity of weight mg : 
Thickness : ………….mm 
Hardness : …..KN or Kg/cm2 
Disintegration time: NMT…..min. 
Friability : NMT………%w/w 
Assay : As per the label claim 
Dissolution:…………….% 
6. Coating  
 
 
Pan speed and spray 
rate 
Pan speed 




Average weight : …..mg±5% 
Weight of 20 tablets :…..mg 
Thickness : …….mm 
Disintegration time: NMT….min. 
Assay : As per the label claim 
Dissolution: …………….% 
 
INDUSTRIAL PROCESS EVALUATION AND 
SELECTION FOR TABLETS 
Determine the unit operations needed to manufacture the 
tablets. 
1. Mixing or Blending 
Mixing or blending ensures production of uniform mixture 
of active pharmaceutical ingredients and excipients that do 
not segregate post blending. So this step is carefully 
scrutinized and validated. Parameters to consider: 
 Mixing or blending technique 
 Mixing or blending speed 
 Mixing or blending time:  
 Drug uniformity 
 Excipient uniformity 
 Equipment capacity/load . 
2. Wet Granulation 
Different types of wet granulation techniques can be used 
such as low shear (e.g., Hobart), high shear (e.g., Diosna, 
GEI-Collette) or fluid bed (e.g., Glatt, Fluid Air). Each 
technique will produce granules with different physical 
properties and will require monitoring of different 
processing parameters. Wet granulation parameters to be 
considered during development and validation are: 
 Binder addition 
 Binder concentration 
 Amount of binder solution/granulating solvent 
 Binder solution/granulating solvent addition  
 Mixing time 
 Granulation end point 
3. Wet Milling 
The wet granulation might need to be milled to break up 
the lumps and enhance drying of the granulation. Wet 
granules that have a wide aggregate range can lead to 
inefficient drying (long drying times and partially dried 
large granules or lumps). 
Factors to consider are: 
 Equipment size and capacity 
 Screen size 
 Mill speed 
 Feed rate 
4. Drying 
The type of drying technique (e.g., tray, fluid bed, and 
microwave) required for the formulation needs to be 
determined and justified. The type of technique may be 
dependent on such factors as drug or formulation 
properties and equipment availability. Changing dryer 
techniques could affect such tablet properties as hardness, 
disintegration, dissolution, and stability. The optimal 
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moisture content of the dried granulation needs to be 
determined. High moisture content can result in tablet 
picking or sticking to tablet punch surfaces and poor 
chemical stability as a result of hydrolysis.An over dried 
granulation could result in poor hardness and friability. 
Moisture content analysis can he performed using the 
conventional loss-on-drying techniques or such state-of-
the-art techniques as near infrared (NIR) spectroscopy. 
Factors to be considered are: 
1. Inlet/outlet temperature 
2. Airflow 
3. Moisture uniformity 
4. Equipment capability/capacity 
5. Milling 
The milling operation will reduce the particle size of the 
dried granulation. The resultant particle size distribution 
will affect such material properties as flow, 
compressibility, disintegration, and dissolution. An 
optimal particle size/size distribution for the formulation 
will need to be determined. 
Factors to consider in milling are: 
 Mill type 
 Screen size 
 Mill speed 
 Feed rate 
6. Lubrication 
Lubricants are added to reduce the friction during tablet 
ejection between the walls of the tablet and die cavity in 
which the tablet was formed. Factors like amount of 
lubricant added, grade of lubricant used, compatibility with 
other ingredients and mixing time must be considered. 
7. Tablet Compression 
Compression is a critical step in the production of a tablet 
dosage form. The materials being compressed will need to 
have adequate flow and compression properties. The 
material should readily flow from the hopper onto the feed 
frame and into the dies. Inadequate flow can result in “rat 
holing” in the hopper and/or segregation of the blend in the 
hopper/feed frame. This can cause tablet weight and 
content uniformity problems. As for the compressibility 
properties of the formulation, it should be examined on an 
instrumented tablet press. Factors to consider during 
compression are as follows: 
 Tooling 
 Compression speed 
 Compression/ejection force 
The following in-process tests should be examined during 
the compression stage: 
 Appearance 
 Hardness 
 Tablet weight 
 Friability 
 Disintegration 
 Weight uniformity 
8. Tablet Coating 
Tablet coating can occur by different techniques (e.g., 
sugar, film, or compression). Film coating has been the 
most common technique over recent years and will be the 
focus of this section. Key areas to consider for tablet 
coating include the following: 
 Tablet properties 
 Equipment type 
 Coater load 
 Pan speed 
 Spray guns:  
 Tablet flow 
 Inlet/outlet temperature and airflow 
 Coating solution 
 Coating weight 
 Residual solvent level 
9. In-process tests 
 Moisture content of “dried granulation” 
 Granulation particle size distribution 
 Blend uniformity 
 Individual tablet weight 
 Tablet hardness 
 Tablet thickness 
 Disintegration 
 Impurity profile 
10. Finished product tests 
 Appearance 
 Assay 
 Content uniformity 
 Tablet hardness 
 Tablet friability 
 Impurity profile 
 Dissolution 
These key test parameters are the yardsticks by which the 
major processing variables in solid dosage forms are 
evaluated. Some processing variables are: 
 Mixing time and speed in blenders and granulators 
 Solvent addition rates in granulators 
 Time, temperature, and airflow conditions in dryers 
and coaters 
 Screen size, feed rate, and milling speed in mills 
 Machine speed and compression force in tablet 
presses 
Process validation testing is generally done on the first 
three batches of product made in production-size 
equipment. Revalidation testing is only done when a 
“significant” change has occurred. A significant change is 
one that will alter the in-process or final product 
specification established during the validation program or 
a change in formula, process, or equipment.12,17,18 
Basic flowchart for the validation of new and existing 
processes of tablet manufacturing is shown in Figure1 and 
Figure 219. 
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Figure 1: Validation of new processes 
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Figure 2: Validation of existing processes 
ANNUAL PRODUCT REVIEW 
Annual Product Quality Review is an annual quality 
review of licensed medicinal product which is conducted 
with the objective of verifying the consistency of the 
existing process, the appropriateness of current 
specifications for both starting materials and finished 
product to highlight any trends and to identify product and 
process improvements.  
The Annual Product Quality review (APQR) is an 
effective quality improvement tool to enhance the 
consistency of the process and the overall quality of the 
product. The PQR will capture a broader view of product 
data, capturing trends and will help determine the need for 
revalidation and changes, if any. 
The GMPs necessitate annual evaluation of quality 
standards of a drug product to determine the need for 
adjustments in drug product specifications, manufacturing 
and control procedures. Subpart J of 21 CFR 211.180 
mandates establishing a written procedure for the Annual 
Product Review process, while, and recommends review of 
a representative number of approved as well as rejected 
batches. 
The Product Quality Review Report should contain at least 
the following details: 
 A review of starting materials and product contact 
primary packaging materials used for the product, 
especially those from new sources. 
 A review of critical in-process controls and finished 
product results 
 A review of all batches that failed to meet established 
specification(s) and their investigation 
 A review of all significant deviations or non-
conformances, their related investigations, and the 
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effectiveness of resultant corrective and preventive 
actions taken 
 A review of all changes carried out to the processes or 
analytical methods 
 A review of Marketing Authorization variations 
submitted/granted/refused, including those for third 
country (export only) dossiers 
 A review of the results of the stability monitoring 
programme and any adverse trends 
 A review of quality-related product returns, 
complaints and recalls and the investigations 
performed at the time 
 A review of adequacy of any other previous product 
process or equipment corrective actions 
 For new marketing authorizations and variations to 
marketing authorizations, a review of post-marketing 
commitments 
 The qualification status of relevant critical equipment 
and utilities, e.g. HVAC, water, compressed gases, 
etc.20 
CONCLUSION 
It can be stated that process validation is major 
requirement of cGMPs regulation for the process 
efficiency and sturdiness from the review validation data 
on pharmaceutical process validation and process control 
variables of tablets manufacturing processes in industry 
and it is the full fledged quality attributing tool for the 
pharmaceutical industries. Validation is the commonest 
word in the areas of drug development, manufacturing and 
specification of finished products. It also renders reduction 
in the cost linked with process monitoring, sampling and 
testing. The multidisciplinary approach to validation of 
solid dosage form must identify the product and process 
characteristics that must be studied and incorporate 
specific validation tests to ensure that that product will 
meet all quality, manufacturing, and regulatory 
requirements.The validation should start with active 
pharmaceutical ingredient (API) characteristics so that this 
material will be uniform batch after batch, providing a 
solid footing upon which the dosage form will be built. 
Scientific information obtained during the preformulation 
stage can form the basis for a well-designed and 
comprehensive validation program. The parameters chosen 
must be relevant indicators of a controlled process. It is not 
sufficient merely to devise a test and set specifications for 
it; rather, it is desirable to show a cause and effect 
relationship between the parameter tested and control of 
the quality and/or process output. 
 For the tableting procedure, the steps studied include 
powder blending, granulation, particle size, and lubrication 
with compression, coating and drug release studies. Such 
step-wise studies have brought light into the impact of the 
parameters and their interactions and increased the 
understanding of the respective processes and also to 
collect a complete and rational database for the building of 
validation evidence. 
It is concluded from the review that pharmaceutical 
validation and process controls are important to assure that 
the drug product can meet standards for the identity, 
strength, quality, purity and stability. 
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